Sarepta jumps on upcoming release of 3-year Elevidys data
Source: SeekingAlpha
2026-01-23 17:55:25 ET
More on Sarepta Therapeutics
- Sarepta Preliminary Results: Not What The Market Wanted To Hear
- Sarepta Therapeutics: Is Elevidys A Bust?
- Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Sarepta guides Q4 sales below estimates
- Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings
Read the full article on Seeking Alpha
For further details see:
Sarepta jumps on upcoming release of 3-year Elevidys data
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-1.75% G/L:
$16.67 Last:
898,612 Volume:
$17.47 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
